STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells.

导出 LinkOut

翻译打印收藏纠错

作者： Yuying,Zhu ^[1] ; He,Zhang ^[1] ; Xingxing,Han ^[1] ; Zhiyong,Wang ^[1] ; Yanfen,Cui ^[1] ; Ran,Tian ^[1] ; Zhaosong,Wang ^[1] ; Baoai,Han ^[1] ; Jianfei,Tian ^[1] ; Fei,Zhang ^[2] ; Ruifang,Niu ^[3]

作者单位： Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. ^[1] Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. Electronic address: feizhang03@tmu.edu.cn. ^[2] Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. Electronic address: rniu@tmu.edu.cn. ^[3]

关键词 Breast cancer C-MET Drug-resistant ErbB family STAT3